Cargando…

Estrogen Receptor Signaling in Cancer

Estrogen receptor signaling plays an important role not only in breast cancer but also in other cancers including ovarian cancer, prostate cancer and acute myeloid leukemia. This series of articles includes new findings of estrogen receptor co-regulators in breast and ovarian cancer with potential a...

Descripción completa

Detalles Bibliográficos
Autor principal: Langdon, Simon P.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7598632/
https://www.ncbi.nlm.nih.gov/pubmed/32987743
http://dx.doi.org/10.3390/cancers12102744
_version_ 1783602667373723648
author Langdon, Simon P.
author_facet Langdon, Simon P.
author_sort Langdon, Simon P.
collection PubMed
description Estrogen receptor signaling plays an important role not only in breast cancer but also in other cancers including ovarian cancer, prostate cancer and acute myeloid leukemia. This series of articles includes new findings of estrogen receptor co-regulators in breast and ovarian cancer with potential as novel targets for therapy. The major isoforms of estrogen receptor—namely estrogen receptor alpha and estrogen receptor beta—can have opposing functionality and these differing roles are described in reviews of estrogen signaling in prostate and ovarian cancers and acute myeloid leukemia. In breast cancer, mutated forms of the estrogen receptor can be selected for on endocrine treatment and frequently lead to treatment resistance while novel imaging techniques are being evaluated to monitor diagnosis and response to treatment. These developing research fields are overviewed.
format Online
Article
Text
id pubmed-7598632
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-75986322020-10-31 Estrogen Receptor Signaling in Cancer Langdon, Simon P. Cancers (Basel) Editorial Estrogen receptor signaling plays an important role not only in breast cancer but also in other cancers including ovarian cancer, prostate cancer and acute myeloid leukemia. This series of articles includes new findings of estrogen receptor co-regulators in breast and ovarian cancer with potential as novel targets for therapy. The major isoforms of estrogen receptor—namely estrogen receptor alpha and estrogen receptor beta—can have opposing functionality and these differing roles are described in reviews of estrogen signaling in prostate and ovarian cancers and acute myeloid leukemia. In breast cancer, mutated forms of the estrogen receptor can be selected for on endocrine treatment and frequently lead to treatment resistance while novel imaging techniques are being evaluated to monitor diagnosis and response to treatment. These developing research fields are overviewed. MDPI 2020-09-24 /pmc/articles/PMC7598632/ /pubmed/32987743 http://dx.doi.org/10.3390/cancers12102744 Text en © 2020 by the author. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Editorial
Langdon, Simon P.
Estrogen Receptor Signaling in Cancer
title Estrogen Receptor Signaling in Cancer
title_full Estrogen Receptor Signaling in Cancer
title_fullStr Estrogen Receptor Signaling in Cancer
title_full_unstemmed Estrogen Receptor Signaling in Cancer
title_short Estrogen Receptor Signaling in Cancer
title_sort estrogen receptor signaling in cancer
topic Editorial
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7598632/
https://www.ncbi.nlm.nih.gov/pubmed/32987743
http://dx.doi.org/10.3390/cancers12102744
work_keys_str_mv AT langdonsimonp estrogenreceptorsignalingincancer